TELA Bio, Inc. (TELA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

I would now like to turn the conference call over to Louisa Smith. Thank you, Martin. Please go ahead. Thank you, Kelvin, and good afternoon, everyone. Earlier today, Telebio released financial results for the third quarter of 2025. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, Chief Executive Officer, Jeff Blizzard, President, and Roberto Cuca, Chief Operating Officer and Chief Financial Officer. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development and pipeline opportunities, product potential, the impact of various macroeconomic conditions identified in our filings, like changes in surgical procedural volumes, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I'll now turn the call over to Tony. Thank you, Louisa, and good afternoon. Thank you for joining Telebio's third quarter 2025 earnings call. Q3 25 marked another important step forward in Telebio as we continue to execute on expanding our commercial footprint, improving our operating discipline, and strengthening our patient-centric culture. We reported revenue of 20.7 million for the quarter, representing 9% growth over the prior year. Growth w...